Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 4/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 14/20 | 0.54 |
| ▸ | TNKS | O95271 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL75939 | 0.89 | F10 (0.49) | F10PTGS2DDB1CRBN | |
| SCHEMBL28956907 | 0.84 | PTGS2 (0.67) | F10PTGS2 | |
| SCHEMBL28834548 | 0.84 | F10 (0.54) | F10PTGS2 | |
| SCHEMBL19086541 | 0.84 | PTGS2 (0.64) | F10PTGS2 | |
| SCHEMBL19456 | 0.84 | PTGS2 (0.64) | F10PTGS2 | |
| SCHEMBL15846877 | 0.84 | F10 (0.54) | F10PTGS2 | |
| SCHEMBL92872 | 0.84 | PTGS2 (0.64) | F10PTGS2 | |
| SCHEMBL15628319 | 0.84 | F10 (0.54) | F10PTGS2 | |
| SCHEMBL2540317 | 0.84 | F10 (0.54) | F10PTGS2 | |
| SCHEMBL18630668 | 0.84 | F10 (0.54) | F10PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1061 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312320-B2 | Method for synthesizing n-substituted phenyl-5-hydroxymethyl-2-oxazolidinone | HANGZHOU DIKE TECHNOLOGIES CO., LTD. (CN) | 2025-05-27 | — | — | US | claimed |
| CN-115490678-B | Preparation method of high-purity rivaroxaban | 浙江苏泊尔制药有限公司 | 2025-02-18 | — | — | CN | claimed |
| CN-115260117-B | Synthesis method of 4- (4-aminophenyl) morpholin-3-one | 江苏法安德医药科技有限公司 | 2024-05-28 | — | — | CN | claimed |
| CN-115490678-A | Preparation method of high-purity rivaroxaban | 浙江苏泊尔制药有限公司 | 2022-12-20 | — | — | CN | claimed |
| CN-115260117-A | Synthesis method of 4- (4-aminophenyl) morpholine-3-one | 江苏法安德医药科技有限公司 | 2022-11-01 | — | — | CN | claimed |
| CN-115215854-A | Preparation process of efficient rivaroxaban bulk drug | 湖南恒生制药股份有限公司 | 2022-10-21 | — | — | CN | claimed |
| US-20220267284-A1 | METHOD FOR SYNTHESIZING N-SUBSTITUTED PHENYL-5-HYDROXYMETHYL-2-OXAZOLIDINONE | HANGZHOU DIKE TECHNOLOGIES CO., LTD. (CN) | 2022-08-25 | — | — | US | claimed |
| CN-112409286-B | Synthesis method of N-substituted phenyl-5-hydroxymethyl-2-oxazolidinone | 杭州迪克科技有限公司 | 2022-08-05 | — | — | CN | claimed |
| CN-114750054-A | Polishing device and polishing method for integrated display screen | 长沙埃福思科技有限公司 | 2022-07-15 | — | — | CN | claimed |
| CN-114752306-A | Ferromagnetic polishing solution for integrated display screen and preparation method thereof | 长沙埃福思科技有限公司 | 2022-07-15 | — | — | CN | claimed |
| US-20040235824-A1 | Indazole-derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | US | claimed |
| WO-2004101556-A1 | INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | WO | claimed |
| WO-2004101553-A1 | BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | WO | claimed |
| EP-1479676-A1 | Benzimidazole-derivatives as factor xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-11-24 | — | — | EP | claimed |
| EP-1479675-A1 | Indazole-derivatives as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-11-24 | — | — | EP | claimed |
| US-20040204406-A1 | Pyrazole-derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-14 | — | — | US | claimed |
| WO-2004087646-A2 | PYRROLIDINO-1,2-DICARBOXY-1-(PHENYLAMIDE)-2-(4-(3-OXO-MORPHOLINO-4-YL)-PHENYLAMIDE) DERIVATIVES AND RELATED COMPOUNDS FOR USE AS INHIBITORS OF COAGULATION FACTOR XA IN THE TREATMENT OF THROMBO-EMBOLIC DISEASES | MERCK PATENT GMBH (DE) | 2004-10-14 | — | — | WO | claimed |
| WO-2004060887-A1 | METHOD FOR PRODUCING 5-CHLORO-N-({5S)-2-OXO-3-[4-(3-OXO-4-MORPHOLINYL)-PHENYL]-1,3-OXAZOLIDIN-5-YL}-METHYL)-2-THIOPHENE CARBOXAMIDE | BAYER HEALTHCARE AG (DE) | 2004-07-22 | — | — | WO | claimed |
| WO-2004056815-A1 | PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-08 | — | — | WO | claimed |
| WO-2004017963-A1 | BENZIMIDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2004-03-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204406-A1 | Pyrazole-derivatives as factor Xa inhibitors | F11, F5, F12 | F10 11/4885PTGS2 919/4885TNKS 1481/4885 |
| US-20220267284-A1 | METHOD FOR SYNTHESIZING N-SUBSTITUTED PHENYL-5-HYDROXYMETHYL-2-OXAZOLIDINONE | CYP3A5, CYP1A2, CYP3A4 | F10 549/4885PTGS2 1027/4885TNKS 1619/4885 |
| US-12312320-B2 | Method for synthesizing n-substituted phenyl-5-hydroxymethyl-2-oxazolidinone | CYP3A5, CYP1A2, CYP3A4 | F10 549/4885PTGS2 1027/4885TNKS 1619/4885 |
| US-20040235824-A1 | Indazole-derivatives as factor Xa inhibitors | F11, F12, F5 | F10 14/4885PTGS2 456/4885TNKS 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.